Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05025605 · ClinicalTrials.gov registry record · Phase 1
Determining Efficacy and Safety of BXCL501 in Agitation Associated With Pediatric Schizophrenia and Bipolar Disorder
A Phase 1 study of Schizophrenia and Schizo Affective Disorder, sponsored by BioXcel Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 140
- Enrollment target
- 5
- Study locations
NCT05025605 is a Phase 1 study of Schizophrenia and Schizo Affective Disorder that is actively recruiting participants, run by BioXcel Therapeutics. The registered enrollment target is 140 participants, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (36% lower). The trial reports 5 study locations across 4 states.
The verdict
NCT05025605, a Phase 1 study of Schizophrenia and Schizo Affective Disorder, is actively recruiting participants, sponsored by BioXcel Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 140 participants
- Enrollment target
- 5
- Study locations
Study Summary
This is a study of the efficacy and safety of BXCL501 in children and adolescents with acute agitation and either bipolar disorder or schizophrenia.
Conditions Studied
Interventions
- DRUG BXCL501 80 Micrograms
- DRUG Placebo Film
- DRUG BXCL501 120 Micrograms
- DRUG BXCL501 60 Micrograms
Study Locations (5)
Georgia
- BioXcel Clinical Research Site - Atlanta
- Bioxcel Clinical Research Site - Decatur
California
- BioXcel Clinical Research Site - Anaheim
Florida
- Bioxcel Clinical Research Site - Hialeah
Texas
- BioXcel Clinical Research Site - DeSoto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 140 participants |
| Start Date | 2021-08-27 |
| Est. Completion | 2026-12-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05025605
The ClinicalTrials.gov registry entry for NCT05025605 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 140 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (36% lower). The listed sponsor is BioXcel Therapeutics, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Schizophrenia appearing as the primary indexed condition, and to 4 interventions - of which BXCL501 80 Micrograms is the first listed.
NCT05025605 reports 5 study locations spanning 4 distinct geographic areas - top geographies include Georgia, California, Florida.
Frequently Asked Questions
What is clinical trial NCT05025605 about?
NCT05025605 is a clinical study titled "Determining Efficacy and Safety of BXCL501 in Agitation Associated With Pediatric Schizophrenia and Bipolar Disorder". This is a study of the efficacy and safety of BXCL501 in children and adolescents with acute agitation and either bipolar disorder or schizophrenia.
What is the current status of trial NCT05025605?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 140 participants. The study started on 2021-08-27. Estimated completion is 2026-12-31.
What conditions does trial NCT05025605 study?
This clinical trial studies the following conditions: Schizophrenia, Schizo Affective Disorder, Bipolar Disorder I, Bipolar Disorder II, Schizophreniform; Schizophrenic.
What interventions are being tested in trial NCT05025605?
The interventions under investigation include: BXCL501 80 Micrograms (DRUG), Placebo Film (DRUG), BXCL501 120 Micrograms (DRUG), BXCL501 60 Micrograms (DRUG).
Who is sponsoring clinical trial NCT05025605?
This trial is sponsored by BioXcel Therapeutics, which has 13 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05025605 being conducted?
This trial has 5 study locations across California, Florida, Georgia, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Schizophrenia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Tolerability of MDMA in Schizophrenia
RECRUITING · Phase 1
-
Imaging Synapses With [11C] UCB-J in the Human Brain
RECRUITING · Phase 1
-
A Study to Evaluate the Dose Levels, Safety, and Drug Levels of Single KarXT Intramuscular Injection in Participants With Schizophrenia
RECRUITING · Phase 1
-
Proposal To Develop A Rapid And Cost-Effective Diagnostic Test For Schizophrenia
RECRUITING · Phase 1
-
Genetics of Cannabis Use Disorder and Cannabinoid Response in Humans
RECRUITING · Phase 1
-
Cromoglicate Adjunctive Therapy for Outpatients With Schizophrenia
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.